Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: A theoretical modeling analysis

Vaccine

Volumn 19, Issue 25-26, 2001, Pages 3420-3431

  Parent du Châtelet, Isabelle ^a   Gessner, Bradford D ^a   Da Silva, Alfred ^a  

^a Assoc pour l'Aide a la Med Prev   (France)

Author keywords

Cost effectiveness; Mass immunization; Meningococcal vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ADULT; AFRICA; ARTICLE; CHILD; COMPARATIVE STUDY; CONJUGATE; COST EFFECTIVENESS ANALYSIS; EMERGENCY TREATMENT; EPIDEMIC; EPIDEMIC MENINGITIS; HEALTH SURVEY; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MODEL; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION TREES; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MODELS, THEORETICAL; SENEGAL; SENSITIVITY AND SPECIFICITY;

EID: 0035858103     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00066-4     Document Type: Article

References (43)

1. La méningite cérébrospinale en Afrique
2. Response to epidemic meningitis in Africa, 1997
3. Optimiser la riposte aux épidémies de méningite à méningocoque: Rapport d'un atelier d'experts réuinis au CERMES (12 au 14 jenvier 1998, Niamey, Niger)
4. A predictable comeback: The second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995
5. The 1998 Senegal epidemic of meningitis was due to the clonal expansion of A:4:P1.9, clone III-1, sequence type 5 Neisseria meningitides strains
6. Detection of Meningitis epidemics in Africa: A population bases analysis
7. Detecting meningococcal meningitis epidemics in highly-endemic African countries. WHO recommendation
8. Surveillance and control of communicable disease epidemics in refugee population: The case of meningococcal meningitis
9. Meningitis outbreaks and vaccination strategy
10. Epidemic of meningococcal meningitis in Bamako, Mali: Epidemiological features and analysis of vaccine efficacy
11. Une épidémie de méningite à méningocoque dans la région des savannes au Togo en 1997: Investigation et stratégies de contrôle
12. Priority during a meningitis epidemic: Vaccination or treatment?
13. Cinical efficacy of meningococcus group A capsular polyssaccharide vaccine in children three months to five years of age
14. Quantitative determination of human immune response to immunization with meningococcal vaccines
15. Age-specific differences in duration in clinical protection after vaccination with meningococcal polysaccharide A vaccine
16. Meningococcal carriage, meningococcal disease and vaccination
17. Epidemiology and prevention of meningococcal disease
18. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa
19. Emergency vaccination against epidemic meningitis in Ghana: Implications for the control of meningococcal disease in West Africa
20. A cost-effectiveness analysis of vaccination strategies against N. meningitides meningitis in sub-Saharan African countries
21. The 1990 meningococcal meningitis epidemic of Sahr (Chad): How useful was an earlier mass vaccination?
22. Meningococcal immunization and protection from epidemics
23. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants
24. Use and misuse of the term "cost effective" in medicine
25. Detection of meningitis epidemics in Africa: A population-based analysis
26. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-1999
27. Sequelae of epidemic meningococcal meningitis in Africa
28. Epidemic meningococcal disease in Nairobi, Kenya, 1989
29. Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys
30. Meningococcal carriage, meningococcal disease and vaccination
31. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personne
32. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: Prospects for routine immunization of infants and children
33. "Love's labor lost": Failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa
34. Meningococcal vaccine in sub-Saharan Africa
35. Meningococcal vaccine in sub-Saharan Africa
36. Meningococcal vaccine in sub-Saharan Africa
37. Meningococcal vaccine in sub-Saharan Africa
38. Safety and immunogenicity of the three doses of a Neisseria meningitidis A + C diphteria conjugate vaccine in infants from Niger